Stanford doctors are developing a new way to treat antibiotic-resistant infections Medicine


Stanford experts have changed the overall antibiotic to be more effective in dealing with one of the common types of antibiotic-resistant bacteria, given the release of universities.

According to the statements Xinhua, chemists developed a small molecular binding that helps conventional antibiotics penetrate and destroy their targets, according to an article in the American Chemical Society.

A comment, known as r8, helps lead antibiotics with external bacterial defense and encourages them to stay, Alexandra Antonoplis, a chemistry graduate and co-author of the report, was quoted in the statement.

Penetration and perseverance help kill bacteria, such as metaphylline-resistant Staphylococcus aureus, or MRSA, which otherwise would have been avoided by physicians, depending on the discharge.

Adding r8 to vancomycin, defense of the first line against MRSA, according to the experiments carried out by the team, made the new medicine hundreds of times more effective.

The same strategy could also apply to other drugs and infections, except for MRSA, researchers said.

"You do not have to come up with a new medicine," said Paul Wender, a chemistry professor and a member of the Stanford Institute of Cancer, "just need to fix the problems with existing medicines."

In the long term, the new approach could have been good news for public health officials who struggled with how to deal with antibiotic-resistant infections such as MRSA.

MRSA, which often starts on the skin, causes more than half of the infections associated with hospitals in Asia and the Americas, and is the main cause of death among antibiotic-resistant infections, according to relaxation.

Follow Medicine on Facebook and Twitter

Source link